DEFA14A: Unicycive Therapeutics Stockholders Approve All Key Proposals, Including Reverse Stock Split, at Annual Meeting

Unicycive Therapeutics, Inc. announced that its stockholders approved all proposals at the Annual Meeting held on June 9, 2025, including the election of four directors, ratification of its independent accounting firm, and a reverse stock split.

Summary

• Unicycive Therapeutics, Inc. held its Annual Meeting of Stockholders on June 9, 2025.
• As of the record date, April 30, 2025, 126,887,067 total votes were entitled, comprising 120,629,281 common stock votes, 5,068,068 Series A Preferred Stock votes, and 1,189,718 Series B Preferred Stock votes.
• An aggregate of 88,440,393 votes, representing approximately 69.70% of the total voting power, were cast in person or by proxy.
• All four director nominees – Dr. Gaurav Aggarwal, Dr. Shalabh Gupta, Dr. Sandeep Laumas, and D. Sarawati Kenkare-Mitra – were elected to serve until the 2025 Annual Meeting or until their successors are duly elected.
• The appointment of Grassi & Co. CPAs, P.C. as the company's independent registered public accounting firm for the fiscal year ended December 31, 2025, was ratified with 87,758,198 votes For.
• The Reverse Stock Split Proposal was approved by stockholders with 78,097,588 votes For.

Sentiment

Score: 7

Explanation: The sentiment is positive as all management-backed proposals passed, including the election of directors and the strategic approval of a reverse stock split. While there was some dissent on specific votes, the overall outcome reflects shareholder support for the company's current governance and strategic direction.

Positives

• All four nominated directors were successfully elected, indicating shareholder confidence in the proposed board.
• The appointment of Grassi & Co. CPAs, P.C. as the independent auditor was overwhelmingly ratified, ensuring continuity in financial oversight.
• The approval of the Reverse Stock Split Proposal provides the company with a mechanism to potentially increase its stock price, which can be crucial for maintaining listing requirements or improving market perception.

Negatives

• Approximately 11.9 million votes withheld for D. Sarawati Kenkare-Mitra's election, indicating some level of shareholder dissent or concern regarding this nominee.
• Over 9.5 million votes were cast against the Reverse Stock Split Proposal, suggesting a notable portion of shareholders did not support this measure.

Future Outlook

The document does not provide explicit forward-looking statements or guidance beyond the approval of the reverse stock split, which is a strategic tool for future share price management.

Management Comments

• "Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 9, 2025 UNICYCIVE THERAPEUTICS, INC. By: /s/ Shalabh Gupta Shalabh Gupta Chief Executive Officer"

Industry Context

This filing details the routine outcomes of an annual stockholder meeting for a publicly traded biotechnology or pharmaceutical company. The approval of a reverse stock split is a common measure taken by companies, particularly those with lower stock prices, to meet exchange listing requirements or improve stock market perception, a trend observed across various industries, including biotech, where early-stage companies may experience stock price volatility.

Comparison to Industry Standards

• The voter turnout of approximately 69.70% is generally considered a healthy participation rate for an annual meeting, aligning with or exceeding typical institutional investor engagement levels for similar-sized public companies.
• The successful election of all director nominees and ratification of the auditor are standard outcomes for most public companies, indicating stable corporate governance.
• The approval of a reverse stock split is a strategic move often seen in biotech companies like Unicycive Therapeutics, Inc. (UNCY), which may face challenges in maintaining minimum bid price requirements on exchanges like Nasdaq. This action is comparable to similar moves by companies such as Sorrento Therapeutics (SRNE) or Aeterna Zentaris (AEZS) in the past, aiming to improve stock liquidity and compliance with listing rules.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The approval of the reverse stock split could impact the number of shares they hold and the per-share price, potentially affecting liquidity and market perception. The election of directors impacts governance and strategic direction.
• Management: The successful passage of all proposals indicates shareholder support for the current management and their strategic initiatives, including the reverse stock split.

Next Steps

• The elected directors will serve until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified.
• Grassi & Co. CPAs, P.C. will serve as the independent registered public accounting firm for the fiscal year ended December 31, 2025.
• The company is now authorized to proceed with the approved Reverse Stock Split.

Key Dates

Keywords

Unicycive Therapeutics, Annual Meeting, Stockholders, Reverse Stock Split, Director Election, Auditor Ratification, Corporate Governance, SEC Filing, Form 8-K, UNCY, Nasdaq Capital Market